Early Pulmonary Embolism Thrombectomy Device Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Early Pulmonary Embolism Thrombectomy Device Market in 2026?

USD 1,039.8 million in 2026 and USD 2,952.6 million by 2036 at an 11.0% CAGR.

Sales of early pulmonary embolism thrombectomy devices are projected to expand at 11.0% CAGR from 2026 to 2036. The industry valuation is estimated to increase from USD 1,039.8 million in 2026 to USD 2,952.6 million by 2036. Demand is expected to be driven by faster treatment decisions for intermediate-high risk and high-risk PE patients. The 2026 AHA/ACC multisociety acute PE guideline gives clinicians a risk-based framework for diagnosis, hospitalization, and treatment escalation. That care pathway explains why hospitals need clearer triage and imaging handoffs before clot-removal decisions.

Hospital adoption is expected to remain highest in centers that use one PE protocol across emergency care and interventional teams. FDA records show that the FlowTriever2 Catheter received a substantially equivalent decision in March 2025.

Summary of the Early Pulmonary Embolism Thrombectomy Device Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Demand is expected to be driven by faster PE risk review during the early hospital window. Emergency teams need clear rules for moving a patient from imaging to clot removal. Hospitals weigh device use against staff coverage and recovery monitoring. Outcome tracking supports follow-up pathways after acute PE intervention. Procurement decisions improve when outcomes are measured beyond procedure completion.
Product and Segment View	The treatment pathway begins with early mechanical intervention and prioritizes rapid thrombus removal without prolonged drug infusion. Early-Stage Thrombectomy is projected to hold 50.6% share in 2026, attributable to its use before pulmonary embolism progresses to more severe clinical stages. Aspiration Thrombectomy Devices are forecast to represent 30.9% share in 2026, underpinned by their ability to remove thrombus through a catheter-based procedure. Intermediate-High Risk PE is estimated to account for 41.0% share in 2026, owing to the need for timely intervention in patients showing right-heart strain without persistent hemodynamic collapse. Emergency Departments are projected to hold 30.5% share in 2026, supported by their role in rapid diagnosis, stabilization, and referral for thrombectomy procedures.
Geography and Growth Outlook	Country growth depends on emergency-care access, specialist availability, hospital budgets, and the speed of clinical pathway adoption. South Korea is projected to advance at 11.3% CAGR through 2036, led by strong hospital infrastructure and growing access to catheter-based pulmonary embolism treatment. The USA is forecast to record 10.7% CAGR by 2036, reinforced by broad device availability, large hospital budgets, and established interventional care networks. The UK is expected to expand at a measured pace, with adoption shaped by NHS pathway reviews, A&E capacity, and access to specialist thrombectomy teams. Germany and Japan are anticipated to record steady growth, although broader rollout will depend on cost-effectiveness reviews, reimbursement decisions, and hospital-level purchasing priorities.
Competitive Landscape	Competition is concentrated in PE aspiration platforms and adjacent catheter-based therapies. Stryker/Inari and Penumbra hold direct PE thrombectomy evidence. AngioDynamics joins Imperative Care and Inquis Medical in adding new aspiration choices. Boston Scientific remains relevant through ultrasound-assisted catheter therapy. Trial evidence and FDA records now carry more weight in hospital evaluations.
Analyst Perspective	Commercial value depends on selecting the right patient in the PE pathway. Device makers must explain clot removal and blood management in plain clinical terms. Hospitals compare aspiration with anticoagulation and catheter-directed thrombolysis. Early rollout works best when teams document timing and recovery outcomes. - Anurag Sharma, Senior Analyst at Future Market Insights.

Source: FMI's proprietary forecasting model and primary research

How is the early pulmonary embolism thrombectomy device market segmented?

The early pulmonary embolism thrombectomy device industry is segmented by intervention timing, device type, risk category, end user, and region.

The segmentation framework separates when the procedure occurs from the device used and the clinical patient group treated. Intervention Timing tracks immediate ER-based procedures and later escalation after anticoagulation review. Device Type covers aspiration thrombectomy, large-bore mechanical systems, ultrasound-assisted catheter systems, and support catheters. Risk Category separates intermediate-high risk PE from high-risk PE and selected intermediate-risk patients. End User analysis follows emergency departments and procedure suites that control diagnosis and intervention. Regional analysis compares specialist access and payment rules across health systems.

What supports demand for Early-Stage Thrombectomy within the Intervention Timing category?

Early-stage use is expected to gain share when hospitals identify right-heart strain before a rescue pathway begins. Immediate ER-based thrombectomy gives physicians a clear action point after imaging confirms serious PE. Adoption is easier to defend when emergency physicians and interventional teams agree on risk criteria before device choice.

• Early-Stage Thrombectomy (Immediate / ER-Based) is expected to hold 50.6% share in 2026. The lead reflects demand for shorter time between diagnosis and clot removal in selected PE cases. Hospitals gain value when one protocol reduces repeated escalation decisions across the acute-care team.
• Procedure timing is expected to depend on PE response rules and after-hours specialist coverage. Sites with clear handoffs can evaluate catheter-based therapy before anticoagulation-only care becomes the default route.

How do Aspiration Thrombectomy Devices shape demand within the Device Type category?

Aspiration devices match the clinical need to remove clot burden without a long drug-infusion window. The category is easier to justify when physicians need fast thrombus removal and lower systemic lytic exposure. Product comparison is expected to focus on catheter control and blood management.

• Aspiration Thrombectomy Devices are projected to hold 30.9% share in 2026. Their position reflects direct use in mechanical clot removal during acute PE intervention. The category connects device value with procedural control and treatment speed.
• Hospitals compare aspiration platforms with thrombectomy systems used in other vascular procedures. This helps teams separate catheter performance from training needs and support requirements.

How does Intermediate-High Risk PE shape demand within the Risk Category segment?

Intermediate-high risk PE is the main decision point for many thrombectomy programs. The patient is serious enough for urgent review but may not be in shock. Device use is expected to depend on imaging and biomarkers that show right ventricular strain. Hospitals need a clear rule for when anticoagulation alone is not sufficient.

• Intermediate-High Risk (Submassive) PE is estimated to account for 41.0% share in 2026. This segment gives manufacturers the clearest evidence pathway for showing measurable improvement after intervention.
• Risk-based adoption follows venous thromboembolism treatment practice. PE care begins with anticoagulation and moves to intervention only when clinical markers support escalation.

How do Emergency Departments shape demand within the End User category?

Emergency departments are the first location where symptoms and imaging results become a treatment decision. Their role is expected to expand once hospitals build PE response pathways around rapid triage. Device adoption depends on whether the interventional team can respond when the ER identifies a suitable case.

• Emergency Departments are forecast to represent 30.5% share in 2026. The segment leads when ER teams activate imaging and specialist review before the patient deteriorates.
• Emergency demand aligns with interventional cardiology devices. Many PE programs share catheter-lab resources and post-procedure monitoring protocols.

What are the drivers, restraints, and opportunities in the early pulmonary embolism thrombectomy device market?

Faster PE escalation and stronger device evidence are expected to support demand. Adoption slows when staffing and imaging access are not available at the same time.

• Driver: Faster PE escalation is expected to raise demand for devices that remove thrombus during the early hospital window.
• Restraint: Adoption is limited when hospitals cannot staff imaging and interventional coverage during the same shift.
• Opportunity: Device makers gain a better sales case when aspiration performance is measured through right-heart recovery and blood-loss control.

The main growth driver is the need to reduce delay after CT confirms PE and risk markers show strain on the right heart. Hospitals move toward thrombectomy only when teams define which patients need clot removal beyond anticoagulation.

The main restraint is the gap between clearance and routine use across acute-care shifts. PE thrombectomy requires imaging access and trained operators with recovery monitoring. Hospitals often compare the pathway against catheter-directed thrombolysis since drug-based intervention already has a known clinical role in many centers. Procurement is expected to slow when a hospital cannot show enough suitable cases to support training and device cost.

The primary opportunity is a governed PE pathway that states which patients move from anticoagulation to aspiration thrombectomy. Penumbra reported in October 2025 that STORM-PE enrolled 100 patients across 22 international sites. The study gives hospitals a way to discuss pulmonary embolectomy systems and other clot-removal approaches with stronger evidence. Device makers that support protocol training and outcome review are expected to have a clearer commercial case.

Which country CAGRs are profiled in the early pulmonary embolism thrombectomy device market?

Country	CAGR
South Korea	11.3%
USA	10.7%
UK	9.6%
Japan	8.6%
Germany	8.4%

How do country-level CAGRs compare in the early pulmonary embolism thrombectomy device market?

The country comparison shows a tight growth band across mature acute-care systems. South Korea leads the profiled set and the USA follows with the broadest commercial base. The UK and Japan form the next adoption group. Germany records a slower rate in this five-country view but its hospital funding base remains large.

• South Korea records the highest rate in the profiled group due to dense hospital networks and specialist access.
• The USA follows since device availability and established interventional programs support faster adoption in large hospitals.
• The UK remains guided by national procedure review and capacity pressure across emergency services.
• Japan and Germany form the lower growth band in this comparison but both retain large hospital bases for selected procedures.
• The pattern shows gradual separation instead of a sharp divide between fast and slow markets.

The full report provides country-level analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• South Korea combines dense metro hospital access with a high level of specialist equipment capacity. Device sales in South Korea are predicted to advance at 11.3% CAGR by 2036, reinforced by tertiary-care concentration and fast patient transfer routes. Selected PE referral to larger centers supports initial adoption. Uniform adoption remains difficult when training and recovery monitoring differ across hospital levels.
• United States hospitals combine high VTE burden with broad access to interventional teams in large acute-care centers. Device demand in the USA is projected to rise at 10.7% CAGR from 2026 to 2036, driven by PE pathway development and current FDA activity. The large case base and spending environment support evaluation of PE thrombectomy programs. Device clearance still requires clear case rules and dependable recovery monitoring.
• UK adoption is shaped by NHS pathway review and emergency-care pressure. The UK market is forecast to expand at 9.6% CAGR through 2036, supported by formal review of percutaneous thrombectomy and urgent imaging demand. Capacity pressure supports PE triage demand. Local adoption remains restrained when hospitals wait for guidance updates before changing access to catheter-based intervention.
• Japanese hospitals are expected to evaluate PE thrombectomy through age-related clinical need and careful procedure control. Adoption in Japan is projected to rise at 8.6% CAGR during the forecast period, supported by tertiary centers that can coordinate CT imaging and specialist operators. The older population supports acute clot-care planning. Expansion remains measured when smaller hospitals transfer complex PE cases to larger centers.
• Germany has a large hospital funding base and a structured emergency-care system. German demand is estimated to advance at 8.4% CAGR from 2026 to 2036, shaped by specialist selection and cost review. Wider adoption remains slower when hospitals need to justify device cost against anticoagulation and existing catheter-based alternatives.

Who are the notable companies in the early pulmonary embolism thrombectomy device market?

The notable companies include Stryker Corporation / Inari Medical and Penumbra. AngioDynamics joins Imperative Care and Inquis Medical across newer aspiration choices. Boston Scientific remains adjacent through catheter-based PE therapy.

The competitive view is limited to companies with direct PE thrombectomy evidence or a clearly adjacent catheter-based PE role. Mechanical aspiration suppliers compete on clot access and blood management. Adjacent therapy providers remain relevant when hospitals compare aspiration thrombectomy with ultrasound-assisted catheter therapy. Hospital purchasing teams also compare operator support, catheter-lab readiness, and after-hours coverage before moving beyond pilots.

• Stryker Corporation strengthened its PE position through the February 2025 acquisition of Inari Medical. The deal brought FlowTriever for pulmonary embolism and ClotTriever for peripheral thrombectomy into the same portfolio.
• Penumbra competes through Indigo and Lightning Flash systems used for computer-assisted vacuum thrombectomy. Trial evidence now supports a clearer comparison with anticoagulation-only treatment for intermediate-high risk PE.
• AngioDynamics joins Imperative Care and Inquis Medical in adding aspiration choices for hospitals reviewing PE intervention. Boston Scientific remains relevant through EKOS and the wider catheter-directed treatment pathway.

Competitive Benchmarking: Early Pulmonary Embolism Thrombectomy Device Market

Company	PE Thrombectomy Fit	Evidence Position	Commercial Role	Technology Focus
Stryker Corporation / Inari Medical	High	High	Direct PE thrombectomy	Aspiration thrombectomy
Penumbra, Inc.	High	High	Direct PE thrombectomy	Computer-assisted vacuum thrombectomy
AngioDynamics, Inc.	Medium	Medium	Direct PE aspiration clearance	Large-bore aspiration
Imperative Care, Inc.	Medium	Medium	Direct PE thrombectomy clearance	Continuous vacuum aspiration
Inquis Medical	Medium	Medium	Direct PE thrombectomy clearance	Aspiration with reinfusion support
Boston Scientific Corporation	Low	Medium	Adjacent catheter-based PE therapy	Ultrasound-assisted thrombolysis

Scoring basis: High indicates a documented PE thrombectomy system or FDA record tied to clot removal in pulmonary embolism. Medium indicates catheter-based PE intervention relevance without being a pure mechanical thrombectomy platform. Low indicates adjacent treatment relevance within PE intervention.

Key Developments in the Early Pulmonary Embolism Thrombectomy Device Market

• In February 2025, Stryker Corporation: Stryker completed the acquisition of Inari Medical. The transaction gave Stryker the FlowTriever System for pulmonary embolism and ClotTriever for peripheral thrombectomy.
• In September 2025, Imperative Care: The company announced FDA clearance of the Symphony Thrombectomy System to treat pulmonary embolism. The clearance added another large-bore aspiration option for PE intervention.
• In June 2025, Inquis Medical: FDA records show a substantially equivalent decision for the Aventus Thrombectomy System. The record supports current USA validation for another PE clot-removal platform.

Key Players in the Early Pulmonary Embolism Thrombectomy Device Market

Direct Mechanical PE Thrombectomy Providers

• Stryker Corporation / Inari Medical
• Penumbra, Inc.
• AngioDynamics, Inc.
• Inquis Medical

Adjacent Catheter-Based PE Intervention Providers

• Boston Scientific Corporation

Emerging or Adjacent Thrombectomy Technology Providers

• Imperative Care, Inc.

Early Pulmonary Embolism Thrombectomy Device Market - Report Scope

Coverage field	Report scope
Market breakdown	Intervention timing, device type, risk category, end user, and region.
Quantitative Units	USD Million
Market Definition	Mechanical and catheter-based devices used to remove thrombus in early pulmonary embolism treatment after clinical and imaging review.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, and South Korea, with 30+ country coverage in the full report.
Key Companies Profiled	Stryker Corporation / Inari Medical, Penumbra, AngioDynamics, Imperative Care, Inquis Medical, and Boston Scientific.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Early Pulmonary Embolism Thrombectomy Device Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Early Pulmonary Embolism Thrombectomy Device Market by Segments

Early Pulmonary Embolism Thrombectomy Device Market segmented by Intervention Timing:

• Early-Stage Thrombectomy (Immediate / ER-Based)
• Post-Anticoagulation Escalation Thrombectomy
• Rescue Thrombectomy After Thrombolysis Review
• Planned Catheter-Based Removal in Tertiary Centers

Early Pulmonary Embolism Thrombectomy Device Market segmented by Device Type:

• Aspiration Thrombectomy Devices
• Large-Bore Mechanical Thrombectomy Systems
• Ultrasound-Assisted Catheter Systems
• Hybrid Catheter-Based Thrombectomy Systems
• Support Catheters and Introducer Systems

Early Pulmonary Embolism Thrombectomy Device Market segmented by Risk Category:

• Intermediate-High Risk (Submassive) PE
• High-Risk (Massive) PE
• Selected Intermediate-Risk PE
• Recurrent PE Requiring Specialist Review

Early Pulmonary Embolism Thrombectomy Device Market segmented by End User:

• Emergency Departments
• Interventional Radiology Suites
• Cardiac Catheterization Laboratories
• Tertiary-Care Hospitals
• Specialty Cardiovascular Centers

Early Pulmonary Embolism Thrombectomy Device Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Imperative Care. (2025, September 2). Imperative Care announces FDA clearance of Symphony Thrombectomy System, the first large-bore continuous vacuum system for treatment of pulmonary embolism.
• Inquis Medical. (2025, June 16). Inquis Medical’s AVENTUS Thrombectomy System receives FDA 510(k) clearance for treatment of pulmonary embolism.
• Stryker Corporation. (2025, February 19). Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment.
• USA Food and Drug Administration. (2025, March 13). 510(k) premarket notification K250088: FlowTriever2 Catheter.
• Boston Scientific Corporation. (2026). EKOS Endovascular System: PE treatment technology.
• USA Food and Drug Administration. (2025, November 24). 510(k) premarket notification K252509: AlphaVac multipurpose mechanical aspiration system F1885.
• Penumbra, Inc. (2026). STORM-PE trial.
• NICE. (2026, January). Percutaneous thrombectomy for acute pulmonary embolism: HealthTech guidance HTG705.
• American Heart Association. (2026, February 19). 2026 guideline for the evaluation and management of acute pulmonary embolism in adults.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the early pulmonary embolism thrombectomy device market in 2026 and 2036?
• Which intervention timing segment leads the market in 2026?
• Why do aspiration thrombectomy devices lead the device type category?
• How does intermediate-high risk PE shape the addressable clinical population?
• Which end-user group leads device adoption in 2026?
• Which countries are profiled for CAGR comparison through 2036?
• Which companies have direct PE thrombectomy evidence or adjacent catheter-based PE intervention relevance?
• How do recent FDA clearances and company announcements affect competition?
• Which restraints limit wider hospital adoption?